PLx Pharma Inc.
NASDAQ Capital MarketCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Natasha Giordano
- Full Time Employees
- 16
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Address
- 9 Fishers Lane Sparta NJ United States of America 07871
- IPO Date
- Mar 13, 2014
- CIK
- 0001497504
- Website
- plxpharma.com
- Similar Companies
- Business
- PLx Pharma Inc. (NASDAQ: PLXP), now trading as PLXPQ following bankruptcy proceedings, operates as a late-stage specialty pharmaceutical company focused on developing and commercializing improved aspirin and nonsteroidal anti-inflammatory drug (NSAID) products via its patented PLxGuard drug delivery system; this platform targets release of active pharmaceutical ingredients into the duodenum to enhance absorption, reduce gastrointestinal side effects such as erosions, ulcers, and bleeding, and improve efficacy over traditional formulations. Core products include the FDA-approved VAZALORE brand of liquid-filled aspirin capsules in 81 mg and 325 mg doses for cardiovascular protection and pain relief, respectively; the pipeline encompasses PL2200 Aspirin formulations, PL1200 Ibuprofen 200 mg for pain and inflammation, and preclinical candidates like GI-safer oral diclofenac and intravenous indomethacin, with potential expansion to other drugs through collaborations. Founded in 2003 and headquartered in Sparta, New Jersey, with prior operations in Houston, Texas, the company targets consumers and healthcare providers in the U.S. market across cardiovascular, pain management, and anti-inflammatory segments. In a major recent development, PLx Pharma entered Chapter 11 bankruptcy in April 2023, announcing delisting from Nasdaq effective April 13, 2023, due to failure to maintain a $1.00 minimum bid price, and executed a stalking horse asset purchase agreement with PLx Acquisition Company LLC for substantially all assets at $100,000 cash plus a $3 million credit bid and liability assumptions, culminating in wind-down operations by September 2023. The firm previously reported declining net sales, such as $0.4 million in Q3 2022 versus $6.6 million year-over-year, amid elevated operating expenses and sales return reserves.
Why Is PLx Pharma (PLXP) Stock Down 32% Today?
Why Is PLx Pharma (PLXP) Stock Down 38% Today?
Spotting Winning Penny Stocks: 3 Top Tips
PLx Pharma (PLXP) Q3 2022 Earnings Call Transcript
PLx Pharma, Inc. (PLXP) Reports Q3 Loss, Misses Revenue Estimates
PLx Pharma Inc. to Report Third Quarter 2022 Financial Results on November 11, 2022, and Provide Business Update
PLx Pharma Inc. (PLXP) CEO, Natasha Giordano on Q2 2022 Results - Earnings Call Transcript
PLx Pharma, Inc. (PLXP) Reports Q2 Loss, Lags Revenue Estimates
PLx Pharma (PLXP) CEO, Natasha Giordano on Q1 2022 Results - Earnings Call Transcript
PLx Pharma, Inc. (PLXP) Reports Q1 Loss, Lags Revenue Estimates
PLx Pharma Inc. to Discuss 2022 First Quarter Financial Results on May 13, 2022 Conference Call and Provide Business Update
PLx Pharma Inc. (PLXP) CEO Natasha Giordano on Q4 2021 Results - Earnings Call Transcript
Dipexium Pharmaceuticals, Inc. (PLXP) Reports Q4 Loss, Misses Revenue Estimates
PLx Pharma Inc. to Present at Oppenheimer & Co's 32nd Annual Healthcare Conference on March 15, 2022
PLx Pharma Inc. to Discuss 2021 Fourth Quarter Financial Results on March 11, 2022 Conference Call and Provide Business Update
Implied Volatility Surging for Dipexium Pharmaceuticals (PLXP) Stock Options
PLx Pharma Inc. to Present at Piper Sandler 33rd Annual Healthcare Conference 2021
PLx Pharma Inc. (PLXP) CEO Natasha Giordano on Q3 2021 Results - Earnings Call Transcript
PLx Pharma Inc. to Discuss 2021 Third Quarter Financial Results on November 12, 2021 Conference Call and Provide Business Update
PLx Pharma stock drops again, and company looks to clarify USPTF's recent comments about aspirin use